DABIGATRAN
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- DABIGATRAN
- Generic name
- DABIGATRAN ETEXILATE
- Manufacturer
- AvPAK
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 39ac558a-b375-f3c1-e063-6394a90aa901
- SPL ID
- 5f52de6a-eae0-0eac-e063-6394a90a90ac
- Version
- 3
- Effective date
- 2026-11-02
- Source export date
- 2026-11-13
- Source partition
- 4
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2aa9706206c534e56285cf80077b2cca2320f0a236e2aa30e80d064749f7c888/drug-label-0004-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:02:40
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 213879 | derived:openfda.application_number |
| application number | ANDA213879 | openfda.application_number | |
| brand name | DABIGATRAN | openfda.brand_name | |
| generic name | DABIGATRAN ETEXILATE | openfda.generic_name | |
| manufacturer name | AvPAK | openfda.manufacturer_name | |
| ndc | package | 50268-200-11 | openfda.package_ndc |
| ndc | package | 50268-200-16 | openfda.package_ndc |
| ndc | product | 50268-200 | openfda.product_ndc |
| ndc11 | package | 50268020011 | derived:openfda.package_ndc |
| ndc11 | package | 50268020016 | derived:openfda.package_ndc |
| rxcui | 1037045 | openfda.rxcui | |
| spl id | 5f52de6a-eae0-0eac-e063-6394a90a90ac | id | |
| spl set id | 39ac558a-b375-f3c1-e063-6394a90aa901 | set_id | |
| unii | SC7NUW5IIT | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF DABIGATRAN INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including dabigatran, increases the risk of thrombotic events. If anticoagulation with dabigatran is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration ( 2.6 , 2.7 , 2.8 ) and Warnings and Precautions ( 5.1 )]. (B) SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with dabigatran who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include: • use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between the administration of dabigatran and neuraxial procedures is not known [see Warnings and Precautions ( 5.3 )]. Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see Warnings and Precautions ( 5.3 )]. Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [see Warnings and Precautions ( 5.3 )]. WARNING: (A) PREMATURE DISCONTINUATION OF DABIGATRAN INCREASES THE RISK OF THROMBOTIC EVENTS, and (B) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning (A) PREMATURE DISCONTINUATION OF DABIGATRAN INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including dabigatran, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if dabigatran is discontinued for a reason other than pathological bleeding or completion of a course of therapy ( 2.6 , 2.7 , 2.8 , 5.1 ). (B) SPINAL/EPIDURAL HEMATOMA: Epidural or spinal hematomas may occur in patients treated with dabigatran who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis ( 5.3 ). Monitor patients frequently for signs and symptoms of neurological impairment and if observed, treat urgently. Consider the benefits and risks before neuraxial intervention in patients who are or who need to be anticoagulated ( 5.3 ).
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS • Bleeding: Dabigatran can cause serious and fatal bleeding ( 5.2 ) • Bioprosthetic heart valves: Dabigatran use not recommended ( 5.4 ) • Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome: Dabigatran use not recommended ( 5.6 ) 5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including dabigatran, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. If dabigatran etexilate capsules is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant and restart dabigatran etexilate capsules as soon as medically appropriate [see Dosage and Administration ( 2.6 , 2.7 , 2.8 )]. 5.2 Risk of Bleeding Dabigatran increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue dabigatran etexilate capsules in patients with active pathological bleeding [see Dosage and Administration ( 2.4 )]. Risk factors for bleeding include the concomitant use of other drugs that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). Dabigatran's anticoagulant activity and half-life are increased in patients with renal impairment [see Clinical Pharmacology ( 12.2 )]. Reversal of Anticoagulant Effect: In adults, a specific reversal agent (idarucizumab) for dabigatran is available when reversal of the anticoagulant effect of dabigatran is needed: • For emergency surgery/urgent procedures • In life-threatening or uncontrolled bleeding In pediatric patients, the efficacy and safety of idarucizumab have not been established. Hemodialysis can remove dabigatran; however the clinical experience supporting the use of hemodialysis as a treatment for bleeding is limited [see Overdosage ( 10 )]. Prothrombin complex concentrates, or recombinant Factor VIIa may be considered but their use has not been evaluated in clinical trials. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of dabigatran. Consider administration of platelet concentrates in cases where thrombocytopenia is present or long-acting antiplatelet drugs have been used. 5.3 Spinal/Epidural Anesthesia or Puncture When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see Boxed Warning ]. To reduce the potential risk of bleeding associated with the concurrent use of dabigatran and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of dabigatran [see Clinical Pharmacology ( 12.3 )] . Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of dabigatran is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known. Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, monitor frequently to detect any signs or symptoms of neurological impairment, such as midline back pain, sensory and motor deficits (numbness, tingling, or weakness in lower limbs), bowel and/or bladder dysfunction. Instruct patients to immediately report if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae. 5.4 Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves The safety and efficacy of dabigatran etexilate capsules in adult patients with bileaflet mechanical prosthetic heart valves was evaluated in the RE-ALIGN trial, in which patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than three months prior to enrollment) were randomized to dose-adjusted warfarin or 150 mg, 220 mg, or 300 mg of dabigatran etexilate capsules twice a day. RE-ALIGN was terminated early due to the occurrence of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) in the dabigatran etexilate capsules treatment arm as compared to the warfarin treatment arm. These bleeding and thromboembolic events were seen both in patients who were initiated on dabigatran etexilate capsules postoperatively within three days of mechanical bileaflet valve implantation, as well as in patients whose valves had been implanted more than three months prior to enrollment. Therefore, the use of dabigatran is contraindicated in all patients with mechanical prosthetic valves [see Contraindications ( 4 )]. The use of dabigatran for the prophylaxis of thromboembolic events in patients with atrial fibrillation in the setting of other forms of valvular heart disease, including the presence of a bioprosthetic heart valve, has not been studied and is not recommended. 5.5 Effect of P-gp Inducers and Inhibitors on Dabigatran Exposure The concomitant use of dabigatran with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided [see Clinical Pharmacology ( 12.3 )]. P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran [see Clinical Pharmacology ( 12.3 )]. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone. Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients Reduce the dosage of dabigatran etexilate capsules to 75 mg twice daily when dronedarone or systemic ketoconazole is co-administered with dabigatran etexilate capsules in patients with moderate renal impairment (CrCl 30 to 50 mL/min). Avoid use of dabigatran etexilate capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15 to 30 mL/min) [see Drug Interactions ( 7.1 ) and Use in Specific Populations ( 8.6 )]. Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism in Adult Patients Avoid use of dabigatran etexilate capsules and concomitant P-gp inhibitors in patients with CrCl < 50 mL/min [see Drug Interactions ( 7.2 ) and Use in Specific Populations ( 8.6 )]. Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Adult Patients Following Hip Replacement Surgery Avoid use of dabigatran etexilate capsules and concomitant P-gp inhibitors in patients with CrCl < 50 mL/min [see Drug Interactions ( 7.3 ) and Use in Specific Populations ( 8.6 )]. Pediatric use information is approved for Boehringer Ingelheim Pharmaceuticals, Inc.’s Pradaxa (dabigatran etexilate) capsules. However, due to Boehringer Ingelheim Pharmaceuticals, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. 5.6 Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome Direct-acting oral anticoagulants (DOACs), including dabigatran, are not recommended for use in patients with triple-positive antiphospholipid syndrome (APS). For patients with APS (especially those who are triple-positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="880.46"> <col width="34.4410876132931%"/> <col width="21.2990936555891%"/> <col width="25.6797583081571%"/> <col width="18.5800604229607%"/> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> </td> <td align="left" styleCode="Rrule" valign="top"> <content styleCode="bold">Dabigatran etexilate capsules </content> <content styleCode="bold">150 mg twice daily N (%)</content> </td> <td align="left" styleCode="Rrule" valign="top"> <content styleCode="bold">Warfarin</content> <content styleCode="bold">N (%)</content> </td> <td align="left" styleCode="Rrule" valign="top"> <content styleCode="bold">Hazard Ratio</content> <content styleCode="bold">(95% CI)c</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Patients</content> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">N=1430</content> </td> <td align="left" styleCode="Rrule" valign="top"> <content styleCode="bold">N=1426</content> </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Major bleeding eventa </td> <td align="center" styleCode="Rrule" valign="top">13 (0.9) </td> <td align="left" styleCode="Rrule" valign="top">25 (1.8) </td> <td align="center" styleCode="Rrule" valign="top">0.54 (0.25, 1.16) </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Fatal bleeding </td> <td align="center" styleCode="Rrule" valign="top">0 </td> <td align="left" styleCode="Rrule" valign="top">1 (0.1) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Bleeding in a critical area or organ </td> <td align="center" styleCode="Rrule" valign="top">7 (0.5) </td> <td align="left" styleCode="Rrule" valign="top">11 (0.8) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Fall in hemoglobin ≥ 2 g/dL or transfusion ≥ 2 units of whole blood or packed red blood cells </td> <td align="center" styleCode="Rrule" valign="top">7 (0.5) </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold"/> 16 (1.1) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Bleeding sites for MBEb </td> <td align="center" styleCode="Rrule" valign="top"> </td> <td align="center" styleCode="Rrule" valign="top"> </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Intracranial </td> <td align="center" styleCode="Rrule" valign="top">2 (0.1) </td> <td align="left" styleCode="Rrule" valign="top">4 (0.3) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Intraocular </td> <td align="center" styleCode="Rrule" valign="top">4 (0.3) </td> <td align="left" styleCode="Rrule" valign="top">2 (0.1) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Retroperitoneal </td> <td align="center" styleCode="Rrule" valign="top">0 </td> <td align="left" styleCode="Rrule" valign="top">1 (0.1) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Intraarticular </td> <td align="center" styleCode="Rrule" valign="top">0 </td> <td align="left" styleCode="Rrule" valign="top">2 (0.1) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Intramuscular </td> <td align="center" styleCode="Rrule" valign="top">0 </td> <td align="left" styleCode="Rrule" valign="top">4 (0.3) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Gastrointestinal </td> <td align="center" styleCode="Rrule" valign="top">4 (0.3) </td> <td align="left" styleCode="Rrule" valign="top">8 (0.6) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Urogenital </td> <td align="center" styleCode="Rrule" valign="top">1 (0.1) </td> <td align="left" styleCode="Rrule" valign="top">1 (0.1) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Other </td> <td align="center" styleCode="Rrule" valign="top">2 (0.1) </td> <td align="left" styleCode="Rrule" valign="top">4 (0.3) </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Clinically relevant non-major bleeding </td> <td align="center" styleCode="Rrule" valign="top">71 (5.0) </td> <td align="center" styleCode="Rrule" valign="top">125 (8.8) </td> <td align="center" styleCode="Rrule" valign="top">0.56 (0.42, 0.75) </td> </tr> <tr> <td styleCode="Lrule Rrule" valign="top">Any bleeding </td> <td align="center" styleCode="Rrule" valign="top">278 (19.4) </td> <td align="left" styleCode="Rrule" valign="top">373 (26.2) </td> <td align="center" styleCode="Rrule" valign="top">0.71 (0.61, 0.83) </td> </tr> </tbody> </table>
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="880.46"> <col width="34.4410876132931%"/> <col width="25.5287009063444%"/> <col width="18.5800604229607%"/> <col width="21.4501510574018%"/> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">Dabigatran etexilate capsules</content> <content styleCode="bold">150 mg twice daily</content> <content styleCode="bold">N (%)</content> </td> <td align="left" styleCode="Rrule" valign="top"> <content styleCode="bold">Placebo</content> <content styleCode="bold">N (%)</content> </td> <td align="left" styleCode="Rrule" valign="top"> <content styleCode="bold">Hazard Ratio</content> <content styleCode="bold">(95% CI)c</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Patients</content> </td> <td align="left" styleCode="Rrule" valign="top"> <content styleCode="bold">N=684</content> </td> <td align="left" styleCode="Rrule" valign="top"> <content styleCode="bold">N=659</content> </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Major bleeding eventa </td> <td align="left" styleCode="Rrule" valign="top">2 (0.3) </td> <td align="left" styleCode="Rrule" valign="top">0 </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Bleeding in a critical area or organ </td> <td align="left" styleCode="Rrule" valign="top">0 </td> <td align="left" styleCode="Rrule" valign="top">0 </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Gastrointestinalb </td> <td align="left" styleCode="Rrule" valign="top">2 (0.3) </td> <td align="left" styleCode="Rrule" valign="top">0 </td> <td align="center" styleCode="Rrule" valign="top"> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Clinically relevant non-major bleeding </td> <td align="center" styleCode="Rrule" valign="top">34 (5.0) </td> <td align="center" styleCode="Rrule" valign="top">13 (2.0) </td> <td align="center" styleCode="Rrule" valign="top">2.54 (1.34, 4.82) </td> </tr> <tr> <td styleCode="Lrule Rrule" valign="top">Any bleeding </td> <td align="left" styleCode="Rrule" valign="top">72 (10.5) </td> <td align="left" styleCode="Rrule" valign="top">40 (6.1) </td> <td align="left" styleCode="Rrule" valign="top">1.77 (1.20, 2.61) </td> </tr> </tbody> </table>
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="100%"> <col width="36%"/> <col width="36%"/> <col width="27%"/> <tbody> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">Dabigatran etexilate capsules</content> <content styleCode="bold">220 mg</content> <content styleCode="bold">N (%)</content> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">Enoxaparin</content> <content styleCode="bold">N (%)</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Patients</content> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">N=1,146</content> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">N=1154</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Major bleeding event </td> <td align="center" styleCode="Rrule" valign="top">23 (2.0) </td> <td align="center" styleCode="Rrule" valign="top">18 (1.6) </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Clinically relevant non-major bleeding </td> <td align="center" styleCode="Rrule" valign="top">48 (4.2) </td> <td align="center" styleCode="Rrule" valign="top">40 (3.5) </td> </tr> <tr> <td styleCode="Lrule Rrule" valign="top">Any bleeding </td> <td align="center" styleCode="Rrule" valign="top">141 (12.3) </td> <td align="center" styleCode="Rrule" valign="top">132 (11.4) </td> </tr> </tbody> </table>
adverse reactions table
<table cellspacing="0" cellpadding="0" border="0" width="100%"> <col width="32%"/> <col width="35%"/> <col width="32%"/> <tbody> <tr styleCode="Botrule"> <td align="center" styleCode="Lrule Rrule" valign="top"> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">Dabigatran etexilate capsules</content> <content styleCode="bold">220 mg</content> <content styleCode="bold">N (%)</content> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">Enoxaparin</content> <content styleCode="bold">N (%)</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top"> <content styleCode="bold">Patients</content> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">N=1,010</content> </td> <td align="center" styleCode="Rrule" valign="top"> <content styleCode="bold">N=1003</content> </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Major bleeding event </td> <td align="center" styleCode="Rrule" valign="top">14 (1.4) </td> <td align="center" styleCode="Rrule" valign="top">9 (0.9) </td> </tr> <tr styleCode="Botrule"> <td styleCode="Lrule Rrule" valign="top">Clinically relevant non-major bleeding </td> <td align="center" styleCode="Rrule" valign="top">26 (2.6) </td> <td align="center" styleCode="Rrule" valign="top">20 (2.0) </td> </tr> <tr> <td styleCode="Lrule Rrule" valign="top">Any bleeding </td> <td align="center" styleCode="Rrule" valign="top">98 (9.7) </td> <td align="center" styleCode="Rrule" valign="top">83 (8.3) </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.